INSM - Insmed Incorporated
About Insmed Incorporated (https://www.insmed.com)
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| William H. Lewis | President, Chief Executive Officer & Chairman | 1969 | $2,467,420 USD |
| Martina Flammer | Chief Medical Officer | 1964 | $1,216,760 USD |
| Roger Adsett | Chief Operating Officer | 1969 | $1,191,652 USD |
| Michael Alexander Smith | Chief Legal Officer & Corporate Secretary | 1978 | $1,138,096 USD |
| Sara Bonstein | Chief Financial Officer | 1981 | $1,117,676 USD |
| S. Nicole Schaeffer | Chief People Strategy Officer | 1968 | $660,810 USD |
| Eugene J. Sullivan FCCP | Chief Product Strategy Officer | 1965 | $593,080 USD |
| Adele Deering | Senior Vice President of Portfolio Strategy & Operational Excellence | – | – |
| Brian K. Kaspar | Chief Scientific Officer | 1974 | – |
| Bryan Dunn | Vice President of Investor Relations | – | – |
| Christie Camelio | Chief Compliance Officer | – | – |
| Claire Mulhearn | Vice President of Corporate Communications | – | – |
| Kevin Mange | Chief Development Officer | – | – |
| Neil Hughes | GM & Head of Europe, Middle East and Africa | – | – |